Clinical-pharmacokinetic aspects of prolonged effect duration as illustrated by β2-agonists

European Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2002, Pages

  Rosenborg, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bambuterol; Formoterol; Prodrugs; Salmeterol

Indexed keywords

BAMBUTEROL; BETA 2 ADRENERGIC RECEPTOR; FORMOTEROL; SALBUTAMOL; TERBUTALINE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE;

ASTHMA; BIOTRANSFORMATION; BODY WEIGHT; BRONCHODILATATION; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYMPTOM; TREATMENT OUTCOME; ARTICLE; BIOLOGICAL MODEL; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SCIENTIFIC LITERATURE; TIME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; DISSERTATIONS, ACADEMIC; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; HUMAN; MODELS, BIOLOGICAL; RECEPTORS, ADRENERGIC, BETA; TERBUTALINE; TIME FACTORS; HUMANS;

EID: 0036315767     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0428-7     Document Type: Review

References (68)

1. Effect of inhaled formoterol and budesonide on exacerbations of asthma
2. Why are long acting beta-adrenoceptor agonists long acting?
3. Differentiation of receptor systems activated by sympathomimetic amines
4. Two new groups of selective stimulants of adrenergic beta-receptors
5. New class of selective stimulants of beta-adrenergic receptors
6. Lack of bronchial beta-adrenoceptor resistance in asthmatics during long-term treatment with terbutaline
7. Beta-adrenergic receptors and their regulation
8. Effects of adrenergic activators and inhibitors on the skeletal muscles
9. Hypokalemia
10. The adrenal glands
11. The autonomic nervous system; the adrenal medulla
12. Disorders of fluid volume, electrolytes, and acid-base balance
13. Risks versus benefits of inhaled beta2-agonists in the management of asthma
14. Sub-sensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients
15. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients
16. The combined effect of theophylline and terbutaline in patients with chronic obstructive airway diseases
17. Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels
18. Terbutaline serum concentrations related to different lung function parameters and beta-receptor function
19. Dose-response relationships of intravenously administered terbutaline in children with asthma
20. Pharmacologic response
21. Kinetics of pharmacological effects
22. Exosites: Their current status, and their relevance to the duration of action of long-acting B2-adrenoceptor agonists
23. 2-receptor stimulant
24. Formoterol fumarate, a new beta2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration
25. Pharmacokinetic parameters of terbutaline in healthy man. An overview
26. Drug latentiation of terbutaline
27. The metabolism and clinical activity of terbutaline and its prodrug ibuterol
28. New lipophilic terbutaline ester prodrugs with long effect duration
29. 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro
30. The design and bioactivation of presystemically stable prodrugs
31. Metabolism of bambuterol in rat liver microsomes: Identification of hydroxylated and demethylated products by liquid chromatography mass spectrometry
32. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterase in human blood
33. Pharmacokinetics of bambuterol in healthy subjects
34. Bambuterol: Clinical effects of three doses of bambuterol once daily in asthmatic patients
35. Bambuterol: A new long acting bronchodilating prodrug
36. Bambuterol: Dose response study of a new terbutaline prodrug in asthma
37. Bambuterol: Effective in nocturnal asthma
38. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration
39. 2-agonist bambuterol in asthmatic patients
40. Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma
41. Oral bambuterol versus terbutaline in patients with asthma
42. Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets
43. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma
44. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids
45. A comparison of two long-acting β-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms
46. Sympathomimetic bronchdilator drugs
47. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
48. Systemic effects of formoterol and salmeterol: A dose response comparison in healthy subjects
49. Determination of bambuterol, a prodrug of terbutaline in plasma and urine by gas chromatography mass spectrometry
50. Quantitative determination of terbutaline in human plasma after administration of bambuterol using coupled columns and electrochemical detection
51. Standardization of spirometry - 1987 update
52. Some problems in biological assay
53. Pharmacokinetics of intravenous terbutaline in asthmatic children
54. Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase
55. Pharmacokinetics and tolerability of formoterol in healthy volunteers after single high dose of Foradil dry powder inhalation via Aerolizer
56. Urinary metabolites of (R),(R)-labetalol
57. Glucuronidation of labetalol at the hydroxy positions by bovine liver microsomes. Isolation, purification, and structure elucidation of the glucuronides of labetalol
58. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate
59. Enantiomeric disposition of inhaled intravenous and oral racemic salbutamol in man - No evidence of enantiomeric lung metabolism
60. Steric aspects of agonism and antagonism at β-adrenoceptors: Synthesis of and pharmacological experiments with the enantiomer of formoterol and their diastereomers
61. Stereoselective glucuronidation of formoterol by human liver microsomes
62. Glucuronidation of drugs
63. Pharmacological and toxicological aspects of drug metabolism
64. Comparative biophysical analysis of the interaction of bronchodilating beta2-adrenoceptor agonists with lipid membranes
65. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - NHLBI/WHO Global initiative for chronic obstructive pulmonary disease (GOLD) workshop summary